Article Listing - Biogen's third-quarter income falls 24% as Avonex fails to match expectations

EC GO-AHEAD FOR DRUG PATENT EXTENSION

9 March 1992

The Council of Ministers of the Commission of the European Community has adopted, as expected, a common position on the...

VARIED FORTUNES FOR COLD REMEDIES

9 March 1992

As far as cold remedies in European markets are concerned, 1991 was a year of mixed fortunes. In some, the...

FRENCH GOVT HEALTH COST DEAL

9 March 1992

The government of France appears at last to be prepared to endorse a new agreement on medical fees and drug...

FRENCH PHARMACY MONOPOLY ROW

9 March 1992

A new round of skirmishes has begun on the French drug "frontier" - the controversial legal borderline that separates drugs,...

PFIZER IN JAPANESE ACQUISITION

9 March 1992

US pharmaceutical concern Pfizer has acquired all outstanding shares of Koshin Medical KK, a medical equipment wholesaler in Japan,...

EC SINGLE MARKET "HYPE" WARNING

9 March 1992

Hans Ruediger Vogel, the director of the German drug industry association, the BPI, has warned against excessive expectations from the...

MERCK AFFIRMS SAFETY of MEVACOR

9 March 1992

Following recent reports that HMG-CoA reductase inhibitor products may have serious side effects, a spokeswoman for Merck has told the...

MAbs MAY PROVIDE MS TREATMENT

9 March 1992

A research project carried out by scientists from Athena Neurosci-ences in collaboration with Stanford University of California, USA, and the...

APPOINTMENTS AT MMD

9 March 1992

At Marion Merrell Dow: Linda Hogan becomes director of licensing; Kevin Hartley named director of taxes; Jill Goodman to...

SB'S GEORGE POSTE

9 March 1992

George Poste, chairman of R&D at SmithKline Beecham Pharmaceuticals, has been elected an executive director of Smith-Kline Beecham plc.

Showing 94731-94740 of 95372 articles

Go to beginningPreviousNextGo to end